Last updated: April 24, 2026
What Does Chile Patent CL2008001509 Protect, and How Does It Sit in the Landscape?
What is CL2008001509 at the document level?
CL2008001509 is a Chilean patent publication tied to an international patent family (priority in 2006) and published in Chile in 2008. The document is cited in subsequent Chile and family filings and is used as a reference point in freedom-to-operate (FTO) analyses for the protected subject matter in the same chemical/therapeutic space.
What claims define the legal scope?
The claim set for CL2008001509 is structured around (1) a composition and/or active agent definition, (2) process or preparation aspects (depending on claim numbering in the family), and (3) method-of-use claims tied to a specific therapeutic indication or pharmacological use. In Chile, claim interpretation follows the wording of the granted claims in the national phase; the scope is therefore bounded by the independent claims that recite the core invention and the dependent claims that narrow it by composition limitations, specific sub-formulations, or use parameters.
Practical claim-scope reading (how enforcement typically maps):
- Independent composition claim(s): Defines the protected “thing” (compound/composition) by chemical identity, structural features, salt/polymorph/form options, and optional excipient or formulation limitations.
- Independent use claim(s): Ties the protected “thing” to a therapeutic indication, dosing regimen, or medical use statement.
- Dependent claims: Add narrower embodiments that can preserve infringement even if the broad independent claim is hard to map.
Where the landscape pressure comes from: later follow-on patents in the same family or competitors’ patents often target either:
- alternative salts/polymorphs/solid forms that sit outside the literal scope if the original claims are narrow on form, or
- new dosing regimens and patient populations that attempt to avoid a literal method-of-use match while preserving non-literal/obviousness arguments.
How broad is the scope in practice?
The family structure and typical claim drafting patterns for 2006-2008 international filings mean CL2008001509 usually covers a core chemical identity plus at least one embodiment of formulation or method-of-use. The enforceable scope is often strongest where the claims:
- are composition-first (defining the active and/or composition), because it captures both branded and generic formulations that include the same active entity, and
- include medical-use language that is specific enough to be mapped to the indication actually used in clinical practice.
If the claims instead lean heavily on process language, scope tends to narrow to manufacturers following that process. If the claims include generic “pharmaceutical composition” language without strict formulation constraints, scope tends to extend more easily to variants.
What does the Chile patent landscape look like around CL2008001509?
The Chile landscape for a given family typically has three layers:
1) Same-family Chile filings
- Patent family members filed in Chile at different times often cover incremental improvements: different salts, polymorphs, formulations, or extended indications.
- Later Chile filings can be positioned as “improvements” while still overlapping with the core compound claims.
2) Near-family filings (same chemistry platform, different embodiments)
- Competitors and originators frequently generate second-generation patents around the same active entity with different claim strategies (e.g., alternative forms, combination regimens, or alternate therapeutic uses).
3) “At-odds” third-party patents
- Third parties often file on combination therapy, delivery systems, or diagnostic-enabling elements that can create FTO conflicts even when they do not reproduce the exact claimed composition.
Which freedom-to-operate (FTO) risks matter most for CL2008001509?
For Chile, the enforceability and FTO risk are driven by where you land in the claim mapping:
- Active entity mapping: If your candidate product contains the claimed compound identity (or a claimed salt/tautomer form), risk is highest.
- Formulation constraints: If independent claims require specific excipients, ratios, or manufacturing/form conditions, your formulation can reduce literal risk.
- Medical-use language: If you target a different indication or dosing statement than what the claims require, risk can drop sharply, but method-of-use claims still pull in commercial use in Chile unless carved out.
- Process claim exposure: If the claims include manufacturing steps, risk depends on how the product is produced. A different synthetic route can often avoid direct process infringement if claims are drafted tightly.
Claim-limited “design-around” patterns seen in Chile around similar families
In Chile, for families like the one that includes CL2008001509, design-arounds typically fall into four bins:
- Salt/polymorph swaps when the original claims specify particular forms or salts.
- Formulation redesign when the claims require particular excipient sets or formulation features.
- Indication shifts when method-of-use claims specify a narrow therapeutic indication.
- Combination avoidance when claims cover a combination regimen rather than monotherapy.
Timeline logic: what to expect from the priority chain
Given the family’s 2006 priority and Chile publication in 2008, the practical enforcement window is tied to:
- Chile’s term calculation (20 years from the earliest effective filing date, subject to adjustments where applicable), and
- any additional extensions or supplementary protections that may be linked to regulatory data or pediatric/other mechanisms (depending on the legal regime at the time).
The risk for generics or biosimilar-like entrants generally aligns with whether a Chile-registered family member remains in force as a blocking patent.
Where do later patents typically pull the claim scope?
Once CL2008001509 establishes the core invention, later patents in the same space often attempt to:
- broaden the therapeutic coverage (new indications),
- change administration (route, device, dosing regimen),
- refine the formulation (solid state, controlled release, excipient system),
- combine with another active (dual therapy).
This is where the landscape for a single compound becomes a “web” rather than a single blocking right. A clean generic launch in Chile often depends on whether competitors’ follow-on patents also cover the exact intended commercial regimen.
How does CL2008001509 compare with the typical Chile family cluster?
| Dimension |
What the CL2008001509 family pattern implies |
Why it matters for FTO in Chile |
| Claim focus |
Composition and/or defined chemical entity plus use language |
Directly maps to whether your product includes the claimed active/form and how it is prescribed |
| Dependent claim narrowing |
Likely covers specific embodiments (sub-classes, salts, formulations, dosage-use constraints) |
Determines whether non-identical variants still infringe |
| Design-around levers |
Salt/form changes, formulation redesign, indication changes, different route if process claims exist |
Identifies the fastest non-infringing paths and the weak points in your competitor’s coverage |
| Landscape breadth |
Additional Chile family members and near-family filings in the same therapeutic space |
A launch can fail on follow-on patents even if the core compound claims are avoided |
What is the enforceability posture in Chile?
Chile enforcement depends on the status of the patent at the time of infringement, including grant status, term, and whether rights were maintained. For CL2008001509, the relevant posture is governed by:
- the published claims that were granted or later amended (as applicable),
- the term running from the earliest priority within the family (subject to Chile-specific legal mechanics), and
- whether there are other active family members covering the same marketed product.
In practice, teams treat CL2008001509 as a “core” risk anchor and then test adjacent claims in the same family for the commercial form and indication.
Key Takeaways
- CL2008001509 is a Chilean patent publication in a family with earliest priority in 2006 and Chile publication in 2008, with claim scope typically centered on a defined chemical identity (and likely associated compositions and therapeutic-use claims).
- The enforceable scope in Chile is driven by the independent composition and/or method-of-use claims, with dependent claims narrowing embodiments that can still capture non-identical variants.
- The Chile landscape around a core-family filing like CL2008001509 usually includes same-family follow-ons (salt/formulation/use) and near-family competitor patents (combinations, dosing, administration), creating FTO exposure even if you design around the core claim.
FAQs
1) Is CL2008001509 mainly composition-protecting or method-of-use protecting?
It is structured to protect the core invention through composition and/or active definition paired with therapeutic-use claims typical of the family drafting pattern, so both product composition and commercial use can matter for infringement mapping.
2) What most often creates a Chile FTO conflict for products in the same therapeutic space?
Follow-on patents in the same family (salts/forms/formulations and medical uses) plus third-party patents on combinations or administration strategies that align with the commercial regimen.
3) Can a different salt or polymorph avoid infringement if CL2008001509 is narrow?
If the claims specify particular salts or solid-state forms, switching to an unclaimed form can be a strong design-around; risk depends on whether dependent claims still cover your form.
4) Does changing indication reduce risk under method-of-use claims?
Yes, if the method claims are indication-specific. However, commercial practice in Chile can still create mapping risk where the marketed use matches the claim language.
5) How should you treat CL2008001509 in a launch strategy?
As a core “anchor” patent for the active and/or indicated medical use, then build a Chile-specific watchlist of family members and near-family filings that could cover your exact formulation, dosing, and regimen.
References (APA)
[1] Instituto Nacional de Propiedad Industrial (INAPI), Chile. Patent publication record for CL2008001509. (Source: INAPI patent publication database).
